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Polyglutamine disorders are chronic, progressive neurodegenerative diseases caused by
expansion of a glutamine tract in widely expressed genes. Despite excellent models of
disease, a well-documented clinical history and progression, and established genetic
causes, there are no FDA approved, disease modifying treatments for these disorders.
Downstream of the mutant protein, several divergent pathways of toxicity have been
identified over the last several decades, supporting the idea that targeting only one
of these pathways of toxicity is unlikely to robustly alleviate disease progression. As a
result, a vast body of research has focused on eliminating the mutant protein to broadly
prevent downstream toxicity, either by silencing mutant protein expression or leveraging
the endogenous protein quality control machinery. In the latter approach, a focus has
been placed on four critical components of mutant protein degradation that are active
in the nucleus, a key site of toxicity: disaggregation, ubiquitination, deubiquitination, and
proteasomal activity. These machineries have unique functional components, but work
together as a cellular defense system that can be successfully leveraged to alleviate
disease phenotypes in several models of polyglutamine toxicity. This review will highlight
recent advances in understanding both the potential and role of these components of
the protein quality control machinery in polyglutamine disease pathophysiology.
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INTRODUCTION
Polyglutamine (polyQ) diseases encompass nine untreatable and invariably fatal neurodegenerative
diseases associated with protein misfolding and aggregation. The cause of this family of disease
is expansion of a glutamine tract within widely differing proteins, leading to gain of function
effects and a shared phenotype of adult-onset progressive neurodegeneration. There are no FDA
approved disease modifying treatments for any polyQ disease despite their well-established genetic
causes, carefully documented clinical history, and the availability of excellent genetic models that
recapitulate aspects of the disease phenotype (Chua and Lieberman, 2013). Work in these model
systems over the last several decades has highlighted downstream toxic effects in a large number of
pathways, including those regulating gene expression, axonal transport, mitochondrial function,
and energy metabolism (Mhatre et al., 1993; Chamberlain et al., 1994; Kazemi-Esfarjani et al.,
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1995; Irvine et al., 2000; McCampbell et al., 2000; Lieberman
et al., 2002; Szebenyi et al., 2003; Morfini et al., 2006;
Ranganathan et al., 2009; Kemp et al., 2011; Giorgetti et al.,
2016; Rocchi et al., 2016). These observations suggest that
targeting any single pathway for therapeutic benefit may be
incomplete and ineffective. As a consequence, strategies to rid
cells of the mutant proteins have attracted considerable recent
attention. Both reducing expression of the mutant protein using
antisense oligonucleotides (Lieberman et al., 2014; Sahashi et al.,
2015; Giorgetti et al., 2016) and enhancing degradation of
the mutant protein (Sittler et al., 2001; Adachi et al., 2003,
2007; Tokui et al., 2009; Wang et al., 2013; Silva-Fernandes
et al., 2014) lead to phenotypic rescue of multiple polyQ
disease models, establishing removal of the mutant protein
as a viable therapeutic strategy. This review will focus on
pathways involved in mutant protein degradation, highlighting
pathophysiologic changes, and possible therapeutic targets
within the fields of ubiquitination, deubiquitinating enzymes,
protein disaggregation, and proteasomal activity. Though
misfolded proteins are also degraded through autophagy, several
excellent recent reviews have detailed the contribution of this
pathway to their clearance and potential strategies for therapeutic
manipulation (Martin et al., 2015; Rusmini et al., 2015, 2016).
UBIQUITINATING ENZYMES (E3s) IN
POLYQ DISEASES
A wealth of studies implicates the ubiquitination machinery as
a potential therapeutic target in polyglutamine diseases. These
enzymes serve a key role in targeting proteins for degradation
both by the proteasome and autophagy (Pratt et al., 2015;
Rusmini et al., 2016). In the last decade, a great deal of focus has
been placed on C-terminal Hsp70-interacting protein (CHIP),
which acts as both a co-chaperone and an E3 ubiquitin ligase
for misfolded proteins and plays a key role in facilitating their
degradation (Pratt et al., 2015).
CHIP’s potential as a therapeutic target centers on its ability
to promote ubiquitination and proteasomal degradation of
client proteins of the Hsp90/Hsp70 based chaperone machinery
(Zhou et al., 2003; Pratt et al., 2015; Chung et al., 2016).
In this machinery, Hsp90 and Hsp70 bind to client proteins
in their native or near native conformations to regulate
many aspects of proteostasis. The binding of Hsp90 to client
proteins regulates hydrophobic protein clefts. Disease-causing
mutations either destabilize clefts or introduce a second site
of inherent instability that also binds chaperones. Interaction
with Hsp90 stabilizes hydrophobic clefts; as mutant proteins
unfold, interaction with Hsp90 is lost, leaving client-bound
Hsp70 to recruit CHIP to promote ubiquitination (Pratt et al.,
2015; Figure 1, middle). Notably, truncated fragments of disease-
causing proteins that lack hydrophobic clefts present in the
full-length protein may fail to interact with the Hsp90/Hsp70
based machinery. This is the case for an amino-terminal
fragment of the polyQ androgen receptor that lacks the ligand-
binding domain. The consequence is that degradation of this
artificial construct is handled differently from the full-length
protein and is largely mediated by autophagy (Wang et al.,
2010).
In our model of chaperone machinery protein triage, Hsp70
binds client proteins and plays a critical role by recruiting CHIP
to misfolded substrates, which in turn promotes ubiquitination
and degradation of these proteins. The recruitment of CHIP may
be influenced by post-translational modifications of Hsp70, such
as phosphorylation of a serine or threonine residue near the
EEVDmotif (VanPelt and Page, 2017). CHIP’s ability to recognize
and ubiquitinateHsp90 clients depends on the binding cleft in the
full-length protein. When CHIP substrates, such as nNOS (Peng
et al., 2004), ErbB2 (Zhou et al., 2003), and estrogen receptor
(Fan et al., 2005), are manipulated by site-specific inhibitors
within the ligand binding cleft, ubiquitination and degradation
are increased (Wijayaratne and McDonnell, 2001; Citri et al.,
2002; Peng et al., 2009), supporting the crucial role of the
ligand binding cleft as a recognition motif for the Hsp70-CHIP
complex.
Due to its ability to ubiquitinate client proteins, CHIP has
been studied extensively in polyQ diseases. In Huntington
disease models, CHIP over-expression suppresses aggregation
and toxicity of polyQ huntingtin both in non-neuronal cells
and primary neurons. In contrast, haploinsufficiency of CHIP
leads to accelerated disease in mice over-expressing polyQ
huntingtin (Miller et al., 2005). CHIP drives degradation of
polyQ huntingtin by promoting ubiquitination and proteasomal
degradation of the mutant protein, an action CHIP can also
perform on ataxin-3, the causative protein in spinocerebellar
ataxia type 3 (SCA3; Jana et al., 2005). Importantly, ataxin-3
deubiquitinates CHIP, terminating CHIP-substrate interaction;
polyQ expansion of ataxin-3 increases its affinity for CHIP and
decreases CHIP levels in SCA3 mice, suggesting a surprising
role for coordinated regulation of CHIP and ataxin-3 as
well as dysregulation of this process in SCA3 (Scaglione
et al., 2011). In spinal and bulbar muscular atrophy (SBMA),
over-expression of CHIP leads to phenotypic rescue of a
transgenic mouse model over-expressing polyQ androgen
receptor. This degradation is selective for the mutant over
the wild type receptor, indicating a preference for misfolded
substrates (Adachi et al., 2007). Recently, CHIP was identified
as a causative gene for autosomal recessive cerebellar ataxia,
further implicating it as a crucial protein in preventing
neurodegeneration and regulating neuronal homeostasis (Shi
et al., 2013).
There is likely functional redundancy between CHIP and
other chaperone-dependent E3 ligases. In support of this notion,
CHIP deletion in cells had no effect on degradation of the
polyQ androgen receptor or the glucocorticoid receptor, which
are both known CHIP substrates (Morishima et al., 2008). To
date no broadly overlapping E3s have been identified, raising the
possibility that multiple E3 ligases are up-regulated in the setting
of CHIP deletion.
Whereas E3s such as CHIP have been shown to play a
protective role in polyQ disease, not all E3s fit this mold
(Figure 1, bottom). TRAF6 is an E3 that is present in polyQ
huntingtin aggregates and ubiquitinates polyQ huntingtin using
lysine residues K6, K27, and K29 within ubiquitin. In cellular
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FIGURE 1 | Pathways regulating polyQ protein degradation through the proteasome. (Top) Insoluble protein aggregates are recognized by Hsp110, which
acts to disaggregate and remove misfolded proteins. These substrates are then passed to the Hsp70/40 complex and subsequently bound by the ubiquitin-
(Continued)
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FIGURE 1 | Continued
associated domain of UBQLN2. UBQLN2 traffics substrates to the proteasome, which recognizes UBQLN2’s ubiquitin-like domain. (Middle) PolyQ proteins that are
clients of the Hsp90/Hsp70 based chaperone machinery include the androgen receptor and huntingtin. Soluble species interact with the chaperone machinery, but
release Hsp90 upon misfolding. This allows substrate bound Hsp70/Hsp40 to recruit E3 ligases, such as CHIP, to promote polyubiquitination and proteasomal
degradation. This action is opposed by deubiquitinating enzymes (DUBs), which can remove the polyubiquitin chains and send soluble polyQ proteins back into the
cellular pool. (Bottom) Though E3 ligases such as CHIP promote K48-linked polyubiquitination and proteasomal degradation, emerging evidence shows that other
E3’s can ubiquitinate using alternative lysine residues, leading to impairment of degradation, increased aggregation, and/or degradation through alternative pathways
such as autophagy. For these ligases, DUBs may act in a beneficial manner to return polyQ proteins to the pool of proteins that can be polyubiquitinated through K48
linkages and degraded through the proteasome.
models, this ubiquitination leads to increased aggregation of
the polyQ protein without a change in wild type huntingtin
localization (Zucchelli et al., 2011). WWP1 is another E3 that
colocalizes with polyQ huntingtin aggregates, and is up-regulated
in both mice and N2a cells expressing polyQ huntingtin.
Interestingly, over-expression ofWWP1 leads to increased polyQ
huntingtin levels and toxicity. The toxic effects of WWP1 have
been attributed to its ability to ubiquitinate polyQ huntingtin at
a K63 residue, leading to reduced proteasomal degradation of the
mutant protein as well as increased toxicity in mouse and cellular
models (Lin et al., 2016).
Together, this evidence provides a framework in which E3s
such as CHIP function together with molecular chaperones to
both recognize and ubiquitinate misfolded protein substrates,
leading to their proteasomal degradation. However, E3s must be
considered on a case by case basis, as growing evidence supports
the idea that non-K48 linked ubiquitination can have opposite
and regulatory effects on cargo. We suggest that enhancing
activity of canonical E3s such as CHIP while inhibiting other E3s
such as TRAF6 and WWP1 may have cooperative therapeutic
benefits to promote polyQ protein degradation.
DEUBIQUITINATING ENZYMES
To counteract the activity of ubiquitin ligases, a system of checks
and balances has been identified and characterized in the form of
a network of deubiquitinating enzymes (DUBs). Over 90 DUBs
have been identified within the human genome, each belonging
to one of seven distinct families. These enzymes play diverse roles
including altering protein function and impacting proteasomal
degradation.
Recently, DUBs have emerged as attractive therapeutic targets
in polyglutamine disorders. By removing ubiquitin tags from
substrates, DUBs can delay proteasomal degradation. In contrast,
their inhibition enhances substrate degradation, demonstrating a
pivotal role in diseases caused bymisfolded protein accumulation
(Hanna et al., 2006; Lee et al., 2010). It is well-established that
DUBs interact with polyQ proteins, such as ataxin-1 (Hong
et al., 2002), ataxin-3 (He et al., 2016), huntingtin (Hyrskyluoto
et al., 2014), and androgen receptor (Dirac and Bernards, 2010;
Burska et al., 2013; Schrecengost et al., 2014; Chen et al., 2015).
However, polyQ proteins can also sequester DUBs, leading
to their inactivation. For example, polyQ ataxin-7 sequesters
USP22 into aggregates and inhibits its DUB activity (Yang et al.,
2015). DUBs can also regulate polyQ proteins. USP19b over-
expression leads to an Hsp90-dependent increase in levels of
wild type and polyQ ataxin-3 as well as polyQ Htt (He et al.,
2016).
One DUB that has attracted considerable attention is USP14,
which binds ubiquitinated substrates and facilitates opening of
the proteasomal gate, allowing for selective and efficient substrate
degradation (Peth et al., 2009). Modulating the activity of this
DUB has significant effects on substrate degradation. Over-
expression of USP14 reduces polyQ huntingtin aggregation
and protects against cell degeneration by inhibiting IRE1α
phosphorylation and blocking ER stress in PC6.3 cells
(Hyrskyluoto et al., 2014). In contrast, Lee et al. have shown that
over-expression of USP14 leads to buildup of both wild type and
polyQ ataxin-3, while pharmacologic inhibition of USP14 leads
to enhanced polyQ ataxin-3 and tau clearance in MEFs (Lee
et al., 2010). These contrary findings may be explained by cell line
or protein specific differences, or effects on total ubiquitin pools
in these cells as a result of modulating global deubiquitination.
Nonetheless, they underscore the physiological importance of
the USP family of DUBs.
DUBs not only modify the degradation and steady state
levels of polyQ proteins, but also influence the function of
their wild type counterparts. DUBs have been intensively
studied in cancer, resulting in the identification of a number
of enzymes that modulate activity of cancer-causing genes.
In particular, androgen receptor, mutations in which cause
both prostate cancer and SBMA, is regulated in diverse ways
by several DUBs. USP26 binds to androgen receptor through
three nuclear receptor interaction motifs, and knockdown of
USP26 leads to decreased receptor activity in LnCaP and
HEK293 cells (Dirac and Bernards, 2010). USP10 is required
for androgen receptor activated transcription of PSA and KLK3,
and this role has been attributed to USP10’s hormone-induced
deubiquitylation of chromatin around androgen regulated
genes (Draker et al., 2011). USP7 shows androgen-dependent
association and deubiquitination of androgen receptor. This
deubiquitination is essential for the androgen responsive
binding to chromatin and subsequent transcriptional activation,
a function that can also be performed by USP12 (Burska
et al., 2013; Chen et al., 2015). The role of these enzymes
in modulating polyQ AR function and toxicity has not yet
been explored. As the physiologic function of many other
polyQ disease causing proteins is not fully understood, how
DUBs may affect their function remains an emerging field of
investigation.
Underscoring the importance of DUBs to polyQ disease is
SCA3, a disorder caused by expansion of a polyQ tract within
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the DUB ataxin-3. This DUB has many important cellular targets
including p53. Interestingly, lack of polyQ ataxin-3’s catalytic
activity leads to increased toxicity in models of SCA3 (Warrick
et al., 2005; Todi et al., 2010). This effect may be due to loss
of protein function or buildup of the toxic protein, which is
less readily recognized by p97 and inefficiently degraded by the
proteasome (Todi et al., 2007). Overall, this work on ataxin-3
and other DUBs shows that this family of proteins serves critical
roles in modulating the function, localization and degradation
of polyQ proteins, and represents an exciting new therapeutic
target.
DISAGGREGATION
Downstream of aggregation, a mechanism of disaggregation
by which cells dismantle inclusions and degrade misfolded
proteins has been characterized as functionally relevant to
polyQ diseases (Figure 1, top). A number of key components
of the mammalian disaggregase machinery have been identified
including heat shock protein 110 (Hsp110; yeast Hsp104),
ubiquilin-2 (UBQLN2), heat shock protein 70 (Hsp70), and heat
shock protein 40 (Hsp40/DnaJ).
Hsp110 is a heat shock inducible protein first shown to
play a key role in stress response and survival, a function
that is conserved from bacteria to yeast and mammalian cells
(Sanchez and Lindquist, 1990; Sanchez et al., 1992; Weber-
Ban et al., 1999). Hsp110 neither promotes proteolysis nor
protects the folded state of denatured luciferase, but mediates
resolubilization of the aggregated protein (Parsell et al., 1994).
The ability to disaggregate denatured luciferase is dependent
on ATP and an intact nucleotide-binding site, suggesting a
role for ATP hydrolysis in disaggregation. This activity is also
dependent on Ydj1, an Hsp40 which promotes ATP hydrolysis,
and Ssa1, a yeast Hsp70, implicating other members of the heat
shock protein family in disaggregation (Glover and Lindquist,
1998).
Hsp110 has been implicated in blocking aggregation and
toxicity of polyQ proteins. Over-expression of yeast Hsp104,
an Hsp110 homolog, reduces aggregation of 72Q and 103Q
huntingtin, and surprisingly, deletion of Hsp104 eliminates
aggregation almost entirely (Krobitsch and Lindquist, 2000).
This finding parallels the effects of Hsp104 on the yeast prion
[PSI+]. These data support a model in which low levels of
Hsp110 play a role in the recognition and seeding of prion-
like aggregates, while high levels lead to recognition and
solubilization of aggregated proteins (Chernoff et al., 1995;
Patino et al., 1996). The role of Hsp110 in disaggregation
of polyQ proteins has also been demonstrated in C. elegans
expressing polyQ-GFP. In this system, over-expression of Hsp110
led to reduced aggregation and rescue of toxicity (Satyal
et al., 2000). Further, over-expression of yeast Hsp104 and
bacterial GroEL in Cos-7 and PC-12 cells reduced aggregation
of polyQ huntingtin, supporting conserved disaggregase activity
in mammalian cells (Carmichael et al., 2002). Using sequential
mass spectrometry in S. cerevisiae, a model of chaperone
binding has started to emerge. Hsp70 and Hsp90 appear to
function in initial recognition of polyQ proteins, and are
released prior to aggregate maturation. Subsequent aggregate
formation occurs prior to Hsp104 interaction, suggesting a
preference of Hsp104 for the aggregated species (Walter et al.,
2011).
In the last several years a new addition to the disaggregase
machinery has been characterized, ubiquilin-2 (UBQLN2).
UBQLN2, also known as hPLIC2, is encoded by an intronless
gene and contains both a ubiquitin-like domain and a ubiquitin-
associated domain (Deng et al., 2011). Early studies showed
that the ubiquitin-associated domain interacts with polyubiquitin
chains on substrates, and the ubiquitin-like domain served to
bring these substrates to and bind the proteasome. However,
these studies also showed that over-expression of UBQLN2
interfered with proteasomal degradation, increasing the half-
life of substrates such as p53 and IκBα (Kleijnen et al., 2000,
2003). Several subsequent studies have corroborated impaired
proteolysis downstream of UBQLN2 over-expression (Chen
and Madura, 2002; Raasi and Pickart, 2003; Massey et al.,
2004). This relationship between substrate recognition and
proteasomal inhibition suggests that UBQLN2 function is best
studied at endogenous levels (Verma et al., 2004). Consistent
with these findings, Hjerpe et al. recently demonstrated a key
role for UBQLN2 in the disaggregase machinery. Knockdown
of UBQLN2 led to reduced survival and inability to clear
insoluble ubiquitin aggregates after heat shock. Importantly, the
clearance of insoluble aggregates was shown to be dependent on
previously mentioned members of the disaggregase machinery
including Hsp70 and Hsp110. The authors also showed that
UBQLN2 colocalizes with polyQ huntingtin aggregates, and
reduction of UBQLN2 led to increased aggregation (Hjerpe et al.,
2016).
The above evidence supports a model in which Hsp70/Hsp110
acts to recognize and solubilize protein aggregates. UBQLN2
associates with client-bound Hsp70 and assists in shuttling
aggregated components to the proteasome. One key remaining
question is whether disaggregation alleviates toxicity in
organismal models of polyglutamine disease, which will identify
the importance of the disaggregation system for therapeutic
strategies. Understanding how to therapeutically manipulate the
disaggregase machinery is a worthwhile endeavor likely to lead
to a better understanding of pathophysiology.
PROTEASOME DYSFUNCTION IN
POLYGLUTAMINE DISEASES
A wealth of evidence has linked the proteasome to several polyQ
diseases, both as a therapeutic target and as a dysfunctional
pathway downstream of mutant polyQ proteins. The 20S
proteasome was first shown to colocalize with aggregates of
polyQ ataxin-1 in both patients and transgenic mice. This same
colocalization was later found in human SCA3 tissue, a mouse
model expressing polyQ ataxin-7, HeLa cells expressing polyQ
androgen receptor, and mice over-expressing truncated polyQ
androgen receptor (Cummings et al., 1998; Chai et al., 1999;
Stenoien et al., 1999; Yvert et al., 2000; Abel et al., 2001).
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Interestingly, in human brain sections from SCA3 patients,
only the 11S and 19S regulatory particles were found in
inclusions, suggesting differential recruitment of proteasomal
components for misfolded aggregates (Schmidt et al., 2002).
Though proteasomes seem to colocalize with the majority of
polyglutamine inclusions, they are not completely trapped, as
some exchange of proteasomes within inclusions was observed
using FRAP (Stenoien et al., 2002).
The proteasome also shows a preference for degrading
misfolded polyQ proteins over their wild type counterparts, likely
due to efficient targeting of mutant proteins for degradation.
In MN1 cells expressing either 24Q or 65Q androgen receptor,
the mutant protein demonstrates significantly reduced half-life,
and this degradation is inhibited by the proteasome inhibitor
lactacystin (Lieberman et al., 2002). Similarly, in cells expressing
20Q and 76Q huntingtin, proteasome inhibition leads to greater
buildup of the toxic, N-terminal polyQ huntingtin compared
to wild type, and dramatically more buildup of the polyQ
protein following proteasome inhibition compared to autophagy
inhibition (Li et al., 2010).
While the proteasome has been implicated in polyQ protein
degradation, studies have also shown impaired function in
several disease models. In mice over-expressing N-terminal
polyQ huntingtin, altered proteasome localization to aggregates
was accompanied by an increase in half-life of the proteasome
substrate p53 (Jana et al., 2001). In cells over-expressing N-
terminal polyQ huntingtin or 1F508 CFTR (cystic fibrosis
transmembrane conductance regulator), cells with aggregates
had a significant impairment in proteasome activity compared
to those lacking aggregates when function was measured by
clearance of the fluorescent reporter protein GFPu (Bence et al.,
2001). Notably, the tight association of aggregation with the
accumulation of GFPu was not reproduced in a mouse model
of Huntington disease (Bett et al., 2009), raising the possibility
that solublemisfolded species of themutant proteinmight impair
proteasome function in some model systems. When SH-SY5Y
cells were stably transfected with polyQ-GFP, there was impaired
ability of the proteasome to compensate for heat shock-induced
stress (Ding et al., 2002). In cerebellar neurons expressing polyQ
ataxin-7, proteasome function was significantly diminished, and
this led to cytosolic accumulation and impaired activity of NF-
κB, culminating in increased activation of caspase-9 (Wang et al.,
2007). The impairment in proteasome function downstream
of polyQ proteins may be indirect, as studies in yeast and
mammalian cells have demonstrated that accumulated substrates
are less likely to be shuttled to the proteasome, potentially due
to dysregulation of the key proteasome chaperone Sis1p or its
mammalian ortholog DnaJB1 (Park et al., 2013). Together, this
evidence suggests a role for proteasome impairment in models of
polyQ diseases.
Though cellular data has been very consistent in
demonstrating proteasome dysregulation, in vivo studies
have lacked consistent results (Bowman et al., 2005; Bennett
et al., 2007; Bett et al., 2009). For example, in R6/2 mice,
which express an N-terminal fragment of polyQ huntingtin,
the proteasome was significantly impaired in synapses of the
striatum and in cultured neurons (Wang et al., 2008), but a
similar effect was not seen at a global level within the brain (Bett
et al., 2009), suggesting compartment specific differences. In
support of this idea, reporter systems have demonstrated that
proteasome activity is markedly lower in neurons compared
to glia, potentially making them more sensitive to functional
changes. Similarly, proteasome activity is lower in neuronal
processes compared to the soma, and lower in the nucleus than
the cytoplasm, reinforcing compartment specific differences that
may impact vulnerability to pathogenesis (Tydlacka et al., 2009;
Zhao et al., 2016).
Perhaps the most compelling evidence for proteasome
dysfunction playing a key role in pathophysiology comes
from successful attempts to modulate degradation through
this pathway, resulting in reduced toxicity in disease models.
Several excellent reviews have highlighted therapeutic strategies
to promote degradation of mutant proteins through the
proteasome, including Hsp90 inhibition (Waza et al., 2006;
Reis et al., 2016), Hsp70 modulation (Pratt et al., 2014, 2015),
and disaggregase enhancement (Shorter, 2017). Importantly,
some of these strategies alleviate polyQ toxicity in the absence
of severe off-target effects, suggesting that they warrant
further exploration as therapeutic approaches for the broad
treatment of polyQ disorders. These studies have spurred diverse
therapeutic efforts which have been recently thoroughly reviewed
(Esteves et al., 2016). The extensive evidence implicating the
proteasome as a therapeutic target, as well as its dysfunction and
mislocalization in polyQ diseases, highlight its importance in the
pathophysiology of disease.
CONCLUSIONS
Recent advances in our understanding of polyQ disease
pathophysiology have shed light on several divergent pathways
of toxicity downstream of the mutant protein (Mhatre et al.,
1993; Chamberlain et al., 1994; Kazemi-Esfarjani et al., 1995;
Irvine et al., 2000; McCampbell et al., 2000; Lieberman et al.,
2002; Szebenyi et al., 2003; Morfini et al., 2006; Ranganathan
et al., 2009; Kemp et al., 2011; Giorgetti et al., 2016; Rocchi
et al., 2016). As a result, a major focus of the field has been on
either preventing synthesis of mutant proteins using antisense
oligonucleotides (Lieberman et al., 2014; Sahashi et al., 2015;
Giorgetti et al., 2016) or enhancing degradation by leveraging
the endogenous cellular machinery (Sittler et al., 2001; Adachi
et al., 2003, 2007; Tokui et al., 2009; Wang et al., 2013;
Silva-Fernandes et al., 2014). The latter approach highlights
the importance of ongoing research into the pathways that
disaggregate, ubiquitinate, deubiquitinate, and degrade mutant
proteins. Potential therapeutic targets have been identified within
all of these key processes, and highlight the possibility of
leveraging existing cell machineries for therapeutic benefit. We
propose that a combination of approaches is likely necessary to
limit polyQ protein toxicity while minimizing off target effects of
therapeutics. The many advances highlighted in this review, as
well as countless others in the fields of mutant gene silencing and
trophic factor stimulation provide an optimistic outlook toward
the future of disease treatments for polyglutamine disorders.
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